EUVIMEDEUVIMED entdecken
Crossref

Trefoil Factor 1 contributes to Paclitaxel and Lapatinib resistance in brain metastatic breast cancer cells

Sumiran Kumar Gurung, Venu Yakati, Raghu Vamsi Kondapaneni, Lalita A Shevde, Shreyas S Rao iD

Biochemistry and Cell Biology · 2026

DOI: 10.1139/bcb-2026-0118 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biochemistry and Cell Biology, 2026. Verfasst von Sumiran Kumar Gurung und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemical and Biological Engineering, The University of Alabama, Tuscaloosa, AL 35487, USA. Hauptthemen laut MEDLINE: Paclitaxel, Lapatinib, Drug Resistance, Neoplasm, Trefoil Factor-1. Die Arbeit nennt 31 Literaturangaben. Gefördert von: American Cancer Society.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Late occurrence of breast cancer brain metastases in patients pretreated with systemic therapies is often associated with therapy resistant brain metastatic lesions. Prior studies targeting previously identified mediators of resistance have yielded limited success, especially in the case of brain metastatic breast cancer (BMBC). Trefoil Factor 1 (TFF1) has been associated with therapy resistance in estrogen receptor (ER) positive breast cancer. However, its role in therapy resistance of triple negative and HER2+ breast cancer remains elusive. Herein, we assessed the involvement of TFF1 in therapy resistant triple negative and HER2+ BMBC. We developed Paclitaxel resistant triple negative and Lapatinib resistant HER2+ BMBC cells by dose escalation method. Drug efflux transporter ABCB1 in Paclitaxel resistant cells and ABCG2 in Lapatinib resistant cells were significantly upregulated. Additionally, cancer stem cell marker, CD24, showed significant upregulation in both resistant cell lines while anti-apoptotic protein BCL2 was upregulated only in Lapatinib resistant cells. Importantly, TFF1 was significantly upregulated in both Paclitaxel and Lapatinib resistant BMBC cells. Moreover, siRNA mediated TFF1 silencing partially alleviated resistance in both Paclitaxel and Lapatinib resistant BMBC cells. Our study shows that TFF1 is potentially associated with resistance to Paclitaxel and Lapatinib in both triple negative and HER2+ BMBC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PaclitaxelLapatinibDrug Resistance, NeoplasmTrefoil Factor-1Brain NeoplasmsBreast NeoplasmsAntineoplastic AgentsHumansFemaleCell Line, Tumor

Stichwörter der Autor:innen

LapatinibPaclitaxelTrefoil Factor 1brain metastatic breast cancerdrug resistance

Substanzen

PaclitaxelLapatinibTrefoil Factor-1TFF1 protein, humanAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Chemical and Biological Engineering, The University of Alabama, Tuscaloosa, AL 35487, USA.
  • Department of Pathology, O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL 35233, USA.

ORCID-Profile: Shreyas S Rao

Förderung

  • American Cancer Society

Zitieren

APA

Gurung, S., Yakati, V., Kondapaneni, R., Shevde, L., & Rao, S. (2026). Trefoil Factor 1 contributes to Paclitaxel and Lapatinib resistance in brain metastatic breast cancer cells. Biochemistry and Cell Biology. https://doi.org/10.1139/bcb-2026-0118

Vancouver

Gurung S, Yakati V, Kondapaneni R, Shevde L, Rao S. Trefoil Factor 1 contributes to Paclitaxel and Lapatinib resistance in brain metastatic breast cancer cells. Biochemistry and Cell Biology. 2026. doi:10.1139/bcb-2026-0118

BibTeX
@article{Gurung2026,
  author = {Gurung, Sumiran Kumar and Yakati, Venu and Kondapaneni, Raghu Vamsi and Shevde, Lalita A and Rao, Shreyas S},
  title = {Trefoil Factor 1 contributes to Paclitaxel and Lapatinib resistance in brain metastatic breast cancer cells},
  journal = {Biochemistry and Cell Biology},
  year = {2026},
  doi = {10.1139/bcb-2026-0118}
}
Kostenlos starten →